Antcin Anti-Cancer Activity: Preclinical Research

Antcins

14+ cancer cell types

Antcins and related triterpenoids from Antrodia camphorata have demonstrated cytotoxic activity against more than 14 human cancer cell lines in preclinical research, with IC50 values as low as 0.6 micromolar.

Lee et al., Anticancer Research, 2012

0.6 μM IC50

antrocin vs. metastatic breast cancer cells

6 cancer types

liver, breast, lung, renal, bone, chondrosarcoma

0 clinical trials

all data remains preclinical

Lee et al., Anticancer Research, 2012

View as image ↗

A single fungal species produces compounds that kill cancer cells in a dish at concentrations lower than some chemotherapy drugs. Antrocin, a sesquiterpene lactone from Antrodia camphorata, achieved an IC50 of 0.6 micromolar against metastatic breast cancer MDA-MB-231 cells, outperforming both doxorubicin and cisplatin in the same assay.^[1] That finding, published in 2011, set off a decade of preclinical work on antcin anti-cancer activity that now spans liver, breast, lung, renal, and bone cancer cell lines.

Every result described in this article comes from cell culture or animal models. No antcin compound has entered human clinical trials for cancer. That gap between petri dish and patient is the central limitation of this entire research field. For background on what these compounds are and how they differ, see Antcins A, B, C, and K: individual compound profiles. For the broader class overview, see antcins: the unique triterpenoids in Antrodia camphorata.

The research landscape: 14+ cell types, zero clinical trials

Lee et al. (2012) conducted the broadest screen to date, testing eleven triterpenoids from Antrodia camphorata against 14 human cancer cell lines and two non-transformed cell types.^[2] Three compounds stood out: antcin A, antcin C, and methyl antcinate A (MAA). All three selectively inhibited tumor cell proliferation over normal cells.

MAA showed the widest spectrum, with cytotoxic activity against KB cells, four oral cancer lines (TSCCa, GNM, OC-2, OEC-M1), pancreatic (Panc-1), breast (BT474), prostate (PC-3), ovarian (OVCAR-3), cervical (HeLa), and bone (U2OS) cancer cells.^[2] IC50 values ranged from 30.2 to 286.4 micromolar, with high selectivity indices indicating preferential toxicity to cancer cells.

That 2012 screening study defined the scope of the field. Subsequent research has drilled into specific compounds against specific cancers, mapping the molecular pathways antcins use to kill cancer cells.

Liver cancer: the most studied target

Liver cancer dominates the antcin anticancer literature, reflecting Antrodia camphorata's traditional use for liver diseases in Taiwan. Three compounds have been tested against hepatocellular carcinoma cells: antcin B, antcin K, and methyl antcinate A.

Antcin B: dual-pathway apoptosis

Hsieh et al. (2011) published the most mechanistically detailed study in this area. Antcin B and its ester derivative methylantcinate B (MAB) induced apoptosis in HepG2 hepatocellular carcinoma cells through both the intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways simultaneously.^[3]

The intrinsic pathway evidence included loss of mitochondrial membrane potential, release of cytochrome c, and activation of caspase-9. The extrinsic pathway evidence included upregulation of Fas and Fas ligand, with activation of caspase-8.^[3] Both pathways converged on caspase-3 activation, PARP cleavage, DNA fragmentation, and chromatin condensation.

A critical detail: NADPH oxidase activation drove reactive oxygen species (ROS) production, and blocking this with the antioxidant N-acetylcysteine reduced both ROS generation and apoptosis. ROS was not a byproduct of cell death but a driver of it.^[3]

Dual-pathway activation is pharmacologically relevant because cancer cells that develop resistance to one apoptotic pathway still face the other. Many conventional chemotherapy agents trigger only one route.

Antcin K: apoptosis through ER and mitochondrial stress

Lai et al. (2016) found that antcin K, the most abundant ergostane triterpenoid in basswood-cultivated Antrodia cinnamomea fruiting bodies, induced apoptosis in Hep 3B hepatoma cells through a sequential stress mechanism.^[4]

The cascade started with ROS generation and ATP depletion, which triggered endoplasmic reticulum (ER) stress. ER stress then caused mitochondrial membrane permeability changes. After mitochondrial membrane potential collapsed, both caspase-independent proteins (HtrA2, apoptosis-inducing factor, endonuclease G) and caspase-dependent proteins (cytochrome c) were released. Cytochrome c activated caspase-9 and caspase-3, which cleaved PARP and drove cell death.^[4]

The mode of death was confirmed as apoptosis, not autophagy or necrosis. Phosphatidylserine exposure (an apoptosis marker) was present, while autophagosome content did not increase and cells did not lyse.

Antcin K: anti-metastasis via integrin suppression

Separately, Huang et al. (2015) showed that antcin K inhibited hepatoma cell metastasis rather than direct killing. In Hep 3B cells, antcin K suppressed adhesion, migration, and invasion within 24 hours of treatment.^[5]

The molecular mechanism involved reduced expression of integrins beta-1, beta-3, alpha-5, and alpha-v. Downstream, phosphorylation of FAK, Src, PI3K, AKT, MEK, ERK, and JNK was suppressed. MMP-2 and MMP-9 (matrix metalloproteinases that break down tissue barriers for metastasis) were reduced in both expression and activity. Simultaneously, E-cadherin was upregulated and vimentin downregulated, indicating reversal of epithelial-to-mesenchymal transition (EMT).^[5]

This means antcin K may have two distinct anti-cancer mechanisms in liver cancer: direct apoptosis induction (Lai et al.) and metastasis suppression (Huang et al.).

Methyl antcinate A: oxidant-mediated mitochondrial death

Hsieh et al. (2010) showed that methyl antcinate A (MAA) induced apoptosis in Huh7 human liver cancer cells through an oxidant-mediated, mitochondrial pathway.^[6]

MAA treatment increased sub-G1 populations, DNA fragmentation, and caspase activation. The pathway involved increased Bax and PUMA expression with disruption of mitochondrial membrane potential. A distinctive feature was cofilin dephosphorylation, which promoted cofilin translocation to mitochondria and accelerated cytochrome c release. ROS scavengers (N-acetylcysteine and Tiron) blocked the entire cascade, confirming ROS as the upstream trigger.^[6]

For how antcins protect healthy liver tissue (a seemingly contradictory function), see how antcins protect the liver: mechanisms of hepatoprotection.

Breast cancer: from Akt inhibition to EMT reversal

Two different Antrodia compounds have been tested against breast cancer cells, attacking different molecular targets.

Antrocin: Akt/mTOR inhibition at sub-micromolar doses

Rao et al. (2011) identified antrocin as the most potent anticancer compound from Antrodia camphorata against metastatic breast cancer. In MDA-MB-231 cells (triple-negative, highly metastatic), antrocin achieved an IC50 of 0.6 micromolar.^[1]

For context, antrocin was a superior antiproliferator compared to doxorubicin and cisplatin in the same cell line. It prevented colony formation and induced dose-dependent apoptosis with caspase-3 cleavage and PARP degradation.^[1]

The mechanism centered on suppression of Akt phosphorylation and its downstream effectors mTOR, GSK-3beta, and NF-kappaB. Anti-apoptotic proteins Bcl-2, Bcl-xL, and survivin decreased in a time-dependent manner, while pro-apoptotic Bax and cytosolic cytochrome c increased.^[1]

The selectivity profile matters: antrocin was non-toxic to non-tumorigenic MCF10A breast cells and HS-68 fibroblasts at the same concentrations that killed cancer cells. This selective toxicity, if it holds in vivo, would distinguish antrocin from conventional chemotherapy agents that damage both cancer and healthy tissue.

Antrocin: in vivo confirmation and cancer stemness suppression

Chen et al. (2019) extended antrocin research beyond cell culture into animal models and cancer stemness. Using public databases, the team first established that increased beta-catenin and Akt expression correlated with drug resistance and poor prognosis in breast cancer patients. In cell culture, antrocin suppressed viability, migration, colony formation, and mammosphere generation (a measure of cancer stem cell activity) by decreasing expression of beta-catenin, Akt, and Notch1.^[10]

The in vivo component is the critical addition: a sequential regimen of antrocin followed by paclitaxel synergistically inhibited breast cancer growth in mice.^[10] This is one of the few studies to move antcin-class compounds beyond the petri dish. The synergy with paclitaxel (a standard chemotherapy drug) raises the possibility that antrocin could serve as an adjunct rather than a standalone agent, though this remains speculative without dose-response and toxicity data from larger animal studies.

Antcin A: reversing epithelial-to-mesenchymal transition

Kumar et al. (2019) explored a different angle. Rather than direct killing, antcin A reversed the epithelial-to-mesenchymal transition (EMT) that allows cancer cells to become motile and invasive.^[7]

Treatment with antcin A upregulated epithelial markers (E-cadherin and occludin) and downregulated mesenchymal markers (N-cadherin and vimentin) through suppression of the transcriptional repressor ZEB1. The upstream mechanism involved p53-mediated activation of microRNA miR-200c, which targets ZEB1 mRNA for degradation.^[7]

This is mechanistically distinct from antrocin's approach. Where antrocin kills cancer cells through Akt/mTOR inhibition, antcin A potentially reverses the invasive phenotype. Whether these two mechanisms could work synergistically has not been tested.

Lung cancer: antrocin and the JAK2/STAT3 pathway

Yeh et al. (2013) demonstrated that antrocin induced apoptosis in lung cancer cells through a mechanism distinct from its activity in breast cancer.^[8]

In lung cancer cell lines, antrocin negatively modulated JAK2/STAT3 signaling. The upstream mediator was microRNA let-7c, which antrocin upregulated. Let-7c then suppressed the JAK2/STAT3 pathway, reducing downstream survival signaling and triggering apoptosis.^[8]

This is a different molecular target than the Akt/mTOR pathway antrocin uses in breast cancer (Rao et al., 2011). The same compound appears to exploit different vulnerabilities in different cancer types. Whether this reflects genuine pathway selectivity or artifacts of cell culture conditions is unknown.

Renal cancer: antcin H and invasion suppression

Chiu et al. (2017) tested antcin H against human renal carcinoma 786-0 cells. The IC50 for growth inhibition was 170 micromolar at 48 hours, making antcin H far less potent than antrocin as a direct cytotoxic agent.^[9]

The more relevant finding was anti-invasive activity at sub-cytotoxic concentrations (below 100 micromolar). At these doses, antcin H suppressed migration and invasion of renal cancer cells through inhibition of FAK and Src kinase activities, decreased paxillin phosphorylation, impaired lamellipodium formation, and upregulated tissue inhibitors of metalloproteinases (TIMPs) while downregulating MMPs, particularly MMP-7.^[9]

The signaling cascade involved ERK1/2 suppression, which decreased the binding of transcription factors C/EBP-beta and c-Fos to the MMP-7 promoter. This provides a mechanistic link between antcin H treatment and reduced invasive capacity.^[9]

Anti-invasive effects at non-toxic doses are a different therapeutic concept than direct cancer cell killing. The idea is that a compound could reduce metastatic spread without the systemic toxicity of cytotoxic chemotherapy. This remains untested in any animal model of renal cancer metastasis.

Bone cancer: antcin K and chondrosarcoma motility

The most recent addition to the antcin anticancer literature appeared in 2025. Law et al. demonstrated that antcin K inhibited migration and invasion in two chondrosarcoma cell lines (the second most common primary bone cancer).^[11]

RNA sequencing identified MMP-7 as the key mediator: antcin K diminished MMP-7 expression, and forced overexpression of MMP-7 reversed the anti-migratory effect. Upstream, antcin K abolished phosphorylation of PI3K (p85 subunit), Akt, mTOR, and NF-kappaB (p65).^[11]

This study mirrors the MMP-suppression mechanism Chiu et al. (2017) found for antcin H in renal cancer. Both compounds reduce matrix metalloproteinase activity to suppress invasion, but through partially overlapping signaling cascades: antcin H works through FAK-ERK-C/EBP-beta/c-Fos, while antcin K works through PI3K/Akt/mTOR/NF-kappaB. The convergence on MMP suppression from different upstream pathways suggests that anti-invasive activity may be a class-wide property of antcins rather than an artifact of a single compound.

Common mechanisms across cancer types

Across all studies, three mechanistic themes recur:

Reactive oxygen species (ROS) generation. Antcin B in liver cancer, methyl antcinate A in liver cancer, and antcin K in hepatoma all used ROS as an upstream trigger for apoptosis. In each case, antioxidants blocked cell death, confirming ROS as causal rather than consequential.^[3][6][4]

Anti-metastatic activity through integrin/FAK/MMP suppression. Antcin K in liver cancer, antcin H in renal cancer, and antcin A in breast cancer all reduced cell migration and invasion by targeting the integrin-FAK signaling axis and/or suppressing matrix metalloproteinases.^[5][9][7]

Selectivity for cancer over normal cells. Lee et al. (2012) showed high selectivity indices for several triterpenoids, and Rao et al. (2011) specifically confirmed non-toxicity to MCF10A and HS-68 normal cells.^[2][1] This selectivity, if reproducible in vivo, would be the most therapeutically relevant property. The test, however, has only been run in two-dimensional cell cultures where cancer cells and normal cells grow under identical, highly artificial conditions.

A 2025 review by Sharif et al. in Naunyn-Schmiedeberg's Archives of Pharmacology summarized the current state of methyl antcinate A research across cancer and inflammation, concluding that structure-activity relationship studies and formulation work represent the most pressing next steps before any clinical translation can begin.^[12]

For context on how other mushroom species compare in cancer research, see Agaricus blazei and cancer research from Brazil and Japan.

What preclinical data cannot tell us

Every study cited in this article used cell culture models (cancer cells grown in plastic dishes) or, at most, rodent models. The limitations of this evidence are structural, not minor:

Pharmacokinetics are unknown. Whether antcins survive digestion, reach tumors at effective concentrations, cross the blood-brain barrier, or accumulate in specific tissues has not been established for any compound discussed here. A compound that kills cancer cells at 0.6 micromolar in a dish is irrelevant if it cannot reach 0.6 micromolar in a tumor.

In vivo tumor models are sparse. Most studies tested compounds against cancer cells in culture. A few used xenograft models in mice, but systematic dose-response, toxicity, and efficacy studies of the type required for drug development have not been published for any individual antcin.

Drug interactions are uncharacterized. How antcins interact with existing chemotherapy agents, whether synergistically or antagonistically, remains unexplored in most combinations.

Source material varies. Antcin content differs dramatically depending on how Antrodia camphorata is cultivated, a factor explored in depth in antcins in Antrodia: Taiwan's most valuable bioactive compound class. Wild fruiting bodies, wood-cultured fruiting bodies, dish cultures, and submerged fermentation mycelia produce different triterpenoid profiles. Research findings from purified compounds may not translate to whole-mushroom preparations.

The distance between these preclinical findings and any clinical application is measured in years of additional research, not months.

The Bottom Line

Antcins from Antrodia camphorata demonstrate preclinical anticancer activity across liver, breast, lung, and renal cancer cell lines through ROS-mediated apoptosis, anti-metastatic signaling, and selective cytotoxicity over normal cells. The compound antrocin achieved sub-micromolar potency against metastatic breast cancer cells. All evidence remains at the cell culture and animal model stage, with no human clinical trials published for any individual antcin compound against any cancer type.

Frequently Asked Questions

What is antcin and where does it come from?

Antcins are ergostane-type triterpenoids unique to Antrodia camphorata (also called Antrodia cinnamomea), a medicinal mushroom endemic to Taiwan. The family includes antcins A, B, C, H, K, and their methylated derivatives. Each has a steroid-like backbone but different side chains that produce different biological activities, from anti-inflammatory to pro-apoptotic to antidiabetic effects.

Can antcin cure cancer?

No human clinical trials have tested any antcin compound against any cancer type. All anticancer data for antcins comes from cell culture experiments and limited animal models. Antrocin achieved an IC50 of 0.6 micromolar against metastatic breast cancer cells in a 2011 study (Rao et al.), and antcin B activated dual apoptotic pathways in liver cancer cells (Hsieh et al., 2011), but these preclinical results have not been validated in humans.

Which antcin compound is most potent against cancer cells?

Antrocin, a sesquiterpene lactone from Antrodia camphorata, showed the lowest IC50 at 0.6 micromolar against MDA-MB-231 metastatic breast cancer cells (Rao et al., 2011). Among the antcin triterpenoids specifically, methyl antcinate A demonstrated the broadest spectrum, with cytotoxic activity against 14 cancer cell types with IC50 values from 30.2 to 286.4 micromolar (Lee et al., 2012).

How do antcins kill cancer cells?

Antcins trigger cancer cell death through multiple pathways depending on the compound. Antcin B activates both intrinsic (mitochondrial) and extrinsic (death receptor) apoptosis simultaneously. Antcin K induces endoplasmic reticulum stress leading to mitochondrial collapse. Antrocin suppresses the Akt/mTOR survival pathway. All three mechanisms involve reactive oxygen species generation as an upstream trigger.

Are antcins toxic to normal cells?

In cell culture, several antcin compounds showed selective toxicity to cancer cells over normal cells. Antrocin was non-toxic to non-tumorigenic MCF10A breast cells and HS-68 fibroblasts (Rao et al., 2011). Lee et al. (2012) reported high selectivity indices for methyl antcinate A across 14 cancer types versus two normal cell lines. These selectivity tests have only been performed in two-dimensional cell cultures, not in living organisms.

Is Antrodia camphorata being developed as a cancer drug?

As of 2026, no antcin compound from Antrodia camphorata has entered formal clinical drug development for cancer. The published research remains at the preclinical stage. Antroquinonol, a different Antrodia compound, has entered clinical trials for non-small cell lung cancer, but the antcin triterpenoids and antrocin have not reached that stage.

Sources & References

1. 1RTHM-00231·Rao, Yerra Koteswara et al. (2011). “Identification of antrocin from Antrodia camphorata as a selective and novel class of small molecule inhibitor of Akt/mTOR signaling in metastatic breast cancer MDA-MB-231 cells..” Chemical research in toxicology.Study breakdown →PubMed →↩
2. 2RTHM-00252·Lee, Yi-Pang et al. (2012). “Anticancer effects of eleven triterpenoids derived from Antrodia camphorata..” Anticancer research.Study breakdown →PubMed →↩
3. 3RTHM-00217·Hsieh, Yun-Chih et al. (2011). “Antcin B and its ester derivative from Antrodia camphorata induce apoptosis in hepatocellular carcinoma cells involves enhancing oxidative stress coincident with activation of intrinsic and extrinsic apoptotic pathway..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
4. 4RTHM-00432·Lai, Chiao-I et al. (2016). “Antcin K, an active triterpenoid from the fruiting bodies of basswood cultivated Antrodia cinnamomea, induces mitochondria and endoplasmic reticulum stress-mediated apoptosis in human hepatoma cells..” Journal of traditional and complementary medicine.Study breakdown →PubMed →↩
5. 5RTHM-00377·Huang, Ya-Ling et al. (2015). “Antcin K, an Active Triterpenoid from the Fruiting Bodies of Basswood-Cultivated Antrodia cinnamomea, Inhibits Metastasis via Suppression of Integrin-Mediated Adhesion, Migration, and Invasion in Human Hepatoma Cells..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
6. 6RTHM-00183·Hsieh, Yun-Chih et al. (2010). “Methyl antcinate A from Antrodia camphorata induces apoptosis in human liver cancer cells through oxidant-mediated cofilin- and Bax-triggered mitochondrial pathway..” Chemical research in toxicology.Study breakdown →PubMed →↩
7. 7RTHM-00565·Kumar, K J Senthil et al. (2019). “Antcin-A Modulates Epithelial-to-Mesenchymal Transition and Inhibits Migratory and Invasive Potentials of Human Breast Cancer Cells via p53-Mediated miR-200c Activation..” Planta medica.Study breakdown →PubMed →↩
8. 8RTHM-00312·Yeh, Chi-Tai et al. (2013). “A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells..” Carcinogenesis.Study breakdown →PubMed →↩
9. 9RTHM-00467·Chiu, Kun-Yuan et al. (2017). “Antcin-H Isolated from Antrodia cinnamomea Inhibits Renal Cancer Cell Invasion Partly through Inactivation of FAK-ERK-C/EBP-β/c-Fos-MMP-7 Pathways..” Evidence-based complementary and alternative medicine : eCAM.Study breakdown →PubMed →↩
10. 10RTHM-00548·Chen, Jia-Hong et al. (2019). “Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling..” Phytomedicine : international journal of phytotherapy and phytopharmacology.Study breakdown →PubMed →↩
11. 11RTHM-00935·Law, Yat-Yin et al. (2025). “Antcin K inhibits chondrosarcoma motility by reducing MMP‑7 expression via downregulation of the PI3K, Akt, mTOR and NF‑κB signaling pathway..” Molecular medicine reports.Study breakdown →PubMed →↩
12. 12RTHM-00950·Sharif, Maria et al. (2025). “Unlocking the biological potential of methyl antcinate A: a new frontier in cancer and inflammation application..” Naunyn-Schmiedeberg's archives of pharmacology.Study breakdown →PubMed →↩